Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France

M. Hiligsmann*, J. -Y. Reginster

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)649-658
Number of pages10
JournalOsteoporosis International
Volume30
Issue number3
DOIs
Publication statusPublished - Mar 2019

Keywords

  • Cost-effectiveness
  • Economic evaluation
  • Osteoporosis
  • Risedronate
  • Treatment
  • QUALITY-OF-LIFE
  • ECONOMIC-EVALUATION
  • INTERVENTION THRESHOLDS
  • ORAL BISPHOSPHONATES
  • EXCESS MORTALITY
  • HIP FRACTURE
  • PERSISTENCE
  • ADHERENCE
  • HOSPITALIZATION
  • BURDEN

Cite this